Immunic, Inc. (IMUX)

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Immunic, Inc. $IMUX Shares Bought by Avidity Partners Management LP

Immunic to Participate in Investor Conferences in July

Immunic to Participate in Investor, Industry and Scientific Conferences in June

As SpaceX reportedly snips IPO valuation, prediction markets are still saying it will be a $2 trillion company

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

FTSE 100 Live: Global markets hit record highs, oil prices slide as Iran deal awaited

Amazon shares have room to run as AWS AI backlog hits $35B, UBS says

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO